Related Experiment Video
Updated: May 6, 2026
08:46
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
12.8K
Translating pharmacogenomics discoveries into the clinic: an implementation framework.
R Stephanie Huang1, Eric R Gamazon2
1Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
Genome Medicine
|October 19, 2013
Summary
Pharmacogenomics implementation is slow due to a lack of standardized translation frameworks. A new system facilitates translating genomic findings into clinical diagnostic tests for common drugs.
Area of Science:
- Genomic Medicine
- Clinical Pharmacology
Background:
- Pharmacogenomics-guided care offers potential for improved patient outcomes.
- Clinical adoption of pharmacogenomics is hindered by challenges in translating research findings into practical diagnostic tools.
Purpose of the Study:
- To describe a comprehensive system for translating genomic findings into clinical practice.
- To demonstrate the system's application using seven commonly prescribed drugs.
Main Methods:
- Development of a standardized framework by the Coriell Personalized Medicine Collaborative.
- Application of the system to facilitate the translation of genomic data into actionable clinical insights.
Main Results:
- The developed system provides a pathway for integrating pharmacogenomic data into routine healthcare.
- Successful application demonstrated for seven frequently prescribed medications, highlighting potential for broader use.
Conclusions:
- A standardized system is crucial for overcoming barriers to pharmacogenomics implementation.
- This framework can accelerate the translation of genomic discoveries into improved patient care and clinical decision-making.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
01:29Pharmacogenetics and Pharmacogenomics: Overview
264
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
264
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
160
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
01:27Pharmacogenetics of Drug Metabolism: Overview
196
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
196
01:27Principles of Pharmacogenetics: Types of Genetic Variants
143
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
143
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
350
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
350